SIONNA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
SIONNA THERAPEUTICS, INC. (SION) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.84M, a 140.92% increase year-over-year.
- SIONNA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.55M, a 212.94% increase year-over-year.
- SIONNA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.31M, a 222.22% increase year-over-year.
- SIONNA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.84M, a 192.48% increase year-over-year.
- SIONNA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.07M, a 225.40% increase from fiscal 2024.
- SIONNA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.71M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.84M 10-Q · filed 2026-08-06 | $13.39M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $6.55M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $12.07M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $3.31M 10-Q · filed 2025-11-05 | $6.15M derived: sum of 2 quarters · filed 2026-08-06 | $8.24M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $2.84M 10-Q · filed 2026-08-06 | $4.93M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.09M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $3.71M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $1.03M 10-Q · filed 2025-11-05 | $2.00M derived: sum of 2 quarters · filed 2025-11-05 | $2.64M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $971.00K 10-Q · filed 2025-11-05 | $1.62M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $647.00K 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |